Product Details
Alunbrig
Brigatinib90 mg
Tablet
DIN/PIN/NPN
02479214
Manufacturer
Takeda Canada Inc.
Formulary Listing Date
2022-02-10
Unit Price
336.9643
Amount MOH Pays
336.9643
Coverage Status
Exceptional Access Program Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
L01ED04
Interchangeable Products
NOLU Clinical Criteria
NOEAP Criteria
Therapeutic Class | Reimbursement Criteria |
---|---|
Oncology Drugs | Brigatinib
Initial Criteria For the treatment of anaplastic lymphoma kinase (“ALK”) – positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) in patients meeting ALL the following criteria:
Exclusion criteria:
Notes:
Renewal Criteria: Recommended dose: Starting dose of 90 mg daily for the first 7 days and, if tolerated, dose increased to 180 mg daily. Approval duration of initial and renewal requests: 1 year EAP Drug Request Form: |